iwCLL

1-888-476-9129 info@bioascend.com

Menu

 

Young Investigator Meeting (YIM)

 

Meeting date is  May 12, 2017!

Overview

One of the goals of the iwCLL is to promote the development of emerging scientists, both clinic- and laboratory-based, who will continue to unravel unanswered questions in CLL. Since 2005, iwCLL has been preceded by a Young Investigator Meeting (YIM), which offers an opportunity for investigators less than 40 years of age to present and discuss their data.

The YIM is a forum for tomorrow’s leaders to network and collaborate with today’s CLL experts. Because of its relaxed atmosphere that facilitates interaction between emerging and established leaders in CLL, the YIM has fostered growth of the field and spurred new research and collaboration.

The purpose of the YIM is to facilitate the professional development of young basic and clinical scientists in the field of CLL research. By providing an opportunity for young investigators to share their research interest in CLL, the YIM planners hope to promote their participation in the iwCLL and encourage their interaction with established senior CLL scientists and investigators to help advance their careers.

–Shih-Shih Chen, MD; 2017 YIM Planning Committee

Description

The YIM is planned as a relaxed forum in which junior researchers—the people normally conducting much of the CLL research under the direction of more senior scientists and clinicians—can discuss their own data and solicit feedback from peers, mentors, and experts.

The full-day YIM preceding the iwCLL will present exciting new concepts emerging from clinic- and laboratory-based research regarding the pathobiology and treatment of CLL, still an incurable disease despite numerous recent breakthroughs. The 2017 YIM will be organized around the following themes, which mirror those of iwCLL:
•  Emerging evidence regarding factors that contribute to the development of CLL
•  Emerging evidence regarding the diagnosis, prognosis, and initial treatment of CLL
•  Emerging evidence regarding factors that contribute to disease evolution and progression
•  Emerging evidence regarding therapy for advanced disease

The YIM is a forum to share critical updates while providing participants an opportunity to make important connections,
gain insight into the latest treatment strategies, and leave inspired to advance the care for patients with CLL.


The majority of the content for the YIM will be derived from selected abstracts. The planners expect the quality of the abstracts to be extremely high, as in past years. In addition, Arnon Kater, MD, PhD (Lymphoma and Myeloma Center, University of Amsterdam, the Netherlands) will discuss pursuing a career in CLL research. A final agenda and faculty list are anticipated in March 2017.

Learning Objectives

After participating in the YIM, participants should be better able to evaluate and interpret the clinical significance of emerging evidence regarding:
• Factors that contribute to the development of CLL
• The diagnosis, prognosis, and initial treatment of CLL
• Factors that contribute to disease evolution and progression treatment of advanced disease
• Treatment of advanced disease

YIM Committee gratefully acknowledges the CLL Global Research Foundation for their generous support and sponsorship of the YIM travel grants

 

Faculty

Shih-Shih Chen, PhD
The Feinstein Institute for Medical Research
Manhasset, New York, United States

Constantine Tam, MD, MBBS
Peter MacCallum Cancer Centre and St. Vincent’s Hospital
East Melbourne, Victoria, Australia

Arnon Kater, MD, PhD
Academic Medical Center
University of Amserdam
Amsterdam, Netherlands

Jacqueline Barrientos, MD
CLL Research and Treatment Program
Northwell Health Cancer Institute
New York, New York, United States

Pablo Oppezzo, PhD
Pasteur Institute of Montevideo
Montevideo, Uruguay

Matthew S. Davids, MD, MMSc
Dana-Farber Cancer Institute
Boston, Massachusetts, United States

Elisa ten Hacken, PhD
Dana-Farber Cancer Institute
Boston, Massachusetts, United States

Jennifer Edelmann, MD
Barts Cancer Institute
London, United Kingdom

Gerardo Ferrer, PhD
The Feinstein Institute for Medical Research
Manhasset, New York, United States

Maria Belén Almejún, PhD
Institute of Experimental Medicine
Buenos Aires, Argentina

Yun Liu, MS
The Feinstein Institute for Medical Research
Manhasset, New York, United States

Shuai Dong, MS
The Ohio State University
Comprehensive Cancer Center
Columbus, Ohio, United States

Stefano Vergani, MS
Hofstra-Northwell School of Medicine
Manhasset, New York, United States

Mercedes Borge, MD
Institute of Experimental Medicine
Buenos Aires, Argentina

Inhye Ahn, MD
National Institutes of Health
Bethesda, Maryland, United States

Katherine Holmes, PhD
St. James’s University Hospital
Leeds, United Kingdom

Leopold Sellner, MD
University Hospital Heidelberg
Heidelberg, Germany

Panagiotis Baliakas, MD, PhD
Uppsala University
Uppsala, Sweden

Othman Al-Sawaf, MD
University Hospital of Cologne
North-Rhine-Westphalia, Germany

Michael Asger Andersen, MD
Rigshospitalet
Copenhagen, Denmark

Clare Sun, MD
National Heart, Lung, and Blood Institute
Bethesda, Maryland, United States

Meixiao Long, MD, PhD
The Ohio State University
Comprehensive Cancer Center
Columbus, Ohio, United States

Iris de Weerdt, MD
Academic Medical Center
University of Amsterdam
Amsterdam, The Netherlands

Chia Sharpe
University of Melbourne
Melbourne, Victoria, Australia

Chi-Ling Chiang
The Ohio State University
Columbus, Ohio, United States

Taylor Rowland, BS
Oregon Health & Science University
Portland, Oregon, United States

Agenda

7:30 am Registration and Breakfast
8:00 am Welcome and Introduction by the YIM Program Committee
Shih-Shih Chen, PhD
8:05 am Emerging Factors That Contribute to the Development of CLL
Chairs: Arnon Kater, MD, PhD and Pablo Oppezzo, PhD
8:05 am

 

Targeting the Spliceosome in a Novel Adoptive Transfer Model of Sf3b1mut/Atmdel Chronic Lymphocytic Leukemia
Elisa ten Hacken, PhD
8:25 am

 

p.P2514fs Mutant NOTCH1 Has Longer Lasting Transcription Factor Activity due to Slower Inactivation and Degradation
Jennifer Edelmann, MD
8:45 am

 

CLL Myeloid-Derived Suppressor Cell Subtypes Correlate With and Polarize T-Cell Subsets Differently
Gerardo Ferrer, PhD
9:05 am

 

Sphingosine Kinase 1 Is Associated With the Activation, Proliferation, and Survival of Chronic Lymphocytic Leukemia Cells
Maria Belen Almejun, PhD
9:25 am The (Auto)Antigen Specificities of B-Cell Receptor Immunoglobulins From CLL Stereotyped Subset 4 Are Positively and Negatively Selected by Structural Elements Introduced by Somatic Mutation and Isotype Class Switching
Yun Liu, MS
9:45 am PI3K p110δ Plays Critical Roles in Chronic Lymphocytic Leukemia Cells and Leukemia T-Cell Immunity
Shuai Dong, MS
10:05 am CLL Stereotyped IGHV-D-J Rearrangements can be Detected in Normal B-Cell Populations Using Ultra-Deep, Next Generation Sequencing Techniques
Stefano Vergani, MS
10:25 am Morning Break
10:40 am Diagnosis, Prognosis, and Initial Treatment of CLL
Session Chairs: Jacqueline Barrientos, MD and Matthew Davids, MD, MMSc
10:40 am Effects of Ibrutinib on Macrophage-Polarization and on the Immune-Response Against Mycobacterium Tuberculosis
Mercedes Borge, MD
11:00 am Combination of Ibrutinib and Short-Course Fludarabine in Previously Untreated Patients With CLL/SLL: A Result of a Pilot Phase II Study
Inhye Ahn, MD
11:20 am Ibrutinib Mediates Changes in Chromatin Structure in Chronic Lymphocytic Leukemia: Epigenetic Studies From the Bloodwise TAP IcICLLe Trial
Katherine Holmes, PhD
11:40 am Cultivation of Leukemia Cells Under Anoxia for the Identification of CLL Patients With Aggressive Clinical Course and Resistance to Chemoimmunotherapy
Leopold Sellner, MD
12:00 pm Cytogenetic Complexity in Chronic Lymphocytic Leukemia: Definitions, Associations With Other Biomarkers, and Clinical Impact
Panagiotis Baliakas, MD, PhD
12:20 pm Impact of Gender on Outcome After Chemoimmunotherapy in Patients With Chronic Lymphocytic Leukemia: A Meta-Analysis of the German CLL Study Group (GCLLSG)
Othman Al-Sawaf, MD
12:40 pm CLL-IPI and IgA Predict Rate of Severe Infections In a Nationwide Study
Michael Andersen, MD
1:00 pm Lunch
2:00 pm Factors Contributing to Disease Evolution and Progression, and Therapy for Advanced Disease
Session Chairs: Shih-Shih Chen, PhD and Constantine Tam, MBBS, MD
2:00 pm Progression on Ibrutinib in Patients With Somatic Mutations in the BCR and NF-kB Pathways
Clare Sun, MD
2:20 pm Ibrutinib Represents a Novel Class of Immune Modulating Therapeutics That Enhances the Survival of Activated T-Cells and Reverses CLL Cell-Mediated Immunosuppression
Meixiao Long, MD, PhD
2:40 pm Rationale for Expansion of Vgamma9Vdelta2 T-Cells for Autologous Cellular Therapy in Chronic Lymphocytic Leukemia in Combination With Ibrutinib
Iris de Weerdt, MD
3:00 pm Comparison of Innate Immunity Changes Following Ibrutinib and Venetoclax Treatment of Relapsed Chronic Lymphocytic Leukemia Patients
Chia Sharpe
3:20 pm Tumor Antigen ROR1 Targeted Delivery of mir-29b in Chronic Lymphocytic Leukemia Induces Epigenetic Reprograming Resulting in Cell Cycle Arrest and Therapeutic Benefit In Vivo
Chi-Ling Chiang
3:40 pm

 

Selective Targeting Cyclin-Dependent Kinase-9 (CDK9) Antagonizes Survival of Neoplastic B-Cells via Deregulation of c-MYC and MCL-1
Taylor Rowland, BS
4:00 pm Afternoon Break
4:20 pm Pursuing a Career in CLL Research
Arnon Kater, MD, PhD
4:50 pm Concluding Remarks and YIM Award by the YIM Program Committee
Shih-Shih Chen, PhD and Nicholas Chiorazzi, MD
5:00 pm Adjourn

 

*Agenda subject to change

Please contact us at  iwcll2017@bioascend.com  for more information.

Microsoft Word - 2017_IWCLLYIM_Invitation[9].docx